Literature DB >> 27604090

Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme.

Mathieu Gautier1, Marianne Perrière, Michael Monet, Alison Vanlaeys, Irina Korichneva, Isabelle Dhennin-Duthille, Halima Ouadid-Ahidouch.   

Abstract

Transient Receptor Potential Melastatin-related 7 (TRPM7) is a non-selective cation channel fused with a functional kinase domain. Physiologically, TRPM7 channel is involved in magnesium homeostasis, cell survival and gastrulation. The channel part is responsible for calcium, magnesium, and metal trace entries. Cation current through TRPM7 channel is inhibited by both intracellular magnesium and magnesium complexed with nucleotides. In parallel, the kinase is able to phosphorylate cytoskeleton proteins like myosin chain regulating cell tension and motility. Moreover, TRPM7 kinase domain can be cleaved by caspase and participates to apoptosis signaling. Importantly, TRPM7 channel expression is aberrant in numerous cancers including breast, glioblastoma, nasopharynx, ovarian, and pancreatic. Moreover, TRPM7 high expression is an independent biomarker of poor outcome in breast cancer. Pharmacological modulation or silencing of TRPM7 strongly affects proliferation, adhesion, migration or invasion in cancer cell lines. Nevertheless, it is still not clear by which mechanism TRPM7 channels may disturb cancer cell hallmarks. In the present review, we will discuss the role of TRPM7 channels in malignancies. In particular, we will distinguish the role of cation signaling from kinase function in order to better understand how TRPM7 channels may play a central role in cancer progression. We will also discuss the recent advances in pharmacological blockers of TRPM7 and their potential use for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27604090     DOI: 10.2174/0929867323666160907162002

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  7 in total

1.  Inhibition of TRPM7 suppresses cell proliferation of colon adenocarcinoma in vitro and induces hypomagnesemia in vivo without affecting azoxymethane-induced early colon cancer in mice.

Authors:  Junhao Huang; Hideki Furuya; Malika Faouzi; Zheng Zhang; Mahealani Monteilh-Zoller; Kelly Galbraith Kawabata; F David Horgen; Toshihiko Kawamori; Reinhold Penner; Andrea Fleig
Journal:  Cell Commun Signal       Date:  2017-08-15       Impact factor: 5.712

Review 2.  Role of TRPM7 in Cancer: Potential as Molecular Biomarker and Therapeutic Target.

Authors:  Nelson S Yee
Journal:  Pharmaceuticals (Basel)       Date:  2017-04-05

3.  TRPM6 is Essential for Magnesium Uptake and Epithelial Cell Function in the Colon.

Authors:  Francesca Luongo; Giuseppe Pietropaolo; Mathieu Gautier; Isabelle Dhennin-Duthille; Halima Ouadid-Ahidouch; Federica I Wolf; Valentina Trapani
Journal:  Nutrients       Date:  2018-06-18       Impact factor: 5.717

4.  TRPM7 Induces Tumorigenesis and Stemness Through Notch Activation in Glioma.

Authors:  Jingwei Wan; Alyssa Aihui Guo; Pendelton King; Shanchun Guo; Talib Saafir; Yugang Jiang; Mingli Liu
Journal:  Front Pharmacol       Date:  2020-12-14       Impact factor: 5.810

5.  The vesicular transfer of CLIC1 from glioblastoma to microvascular endothelial cells requires TRPM7.

Authors:  Dominique Thuringer; Gaetan Chanteloup; Pascale Winckler; Carmen Garrido
Journal:  Oncotarget       Date:  2018-09-07

6.  The Role of Transient Receptor Potential Melastatin 7 (TRPM7) in Cell Viability: A Potential Target to Suppress Breast Cancer Cell Cycle.

Authors:  Hengrui Liu; James P Dilger; Jun Lin
Journal:  Cancers (Basel)       Date:  2020-01-04       Impact factor: 6.639

7.  Expression and prognostic value of TRPM7 in canine mammary tumours.

Authors:  Seulji Lee; Sungin Lee; Wan Hee Kim
Journal:  Vet Comp Oncol       Date:  2021-05-04       Impact factor: 2.613

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.